Ajay Dhakal

Jun 23, 2023 | acsjournals.onlinelibrary.wiley.com | Arya Roy |Vasanthan Muthusamy Kumarasamy |Ajay Dhakal |Ruth O’Regan

Sacituzumab govitecan SG is an ADC comprising humanized immunoglobulin G1 targeting the trophoblast cell surface antigen (Trop2), which is overexpressed in most human solid epithelial cancers, conjugated with the active metabolite of irinotecan (SN-38) by a hydrolysable C2LA covalent linker.31, 32 The conjugate has intermediate serum stability and is cleaved in low pH within the tumor microenvironment and the lysosomes, possessing a DAR of 7.6:1.31 It was initially approved for use in...

Jan 18, 2023 | onclive.com | Ajay Dhakal

Ajay Dhakal, MBBS, assistant professor, Department of Medicine, Hematology/Oncology, the University of Rochester Medical Center, discusses the two key trials supporting the use of pertuzumab (Perjeta) as a standard-of-care regimen in HER2-positive breast cancer.